SCHEMBL4774579

SCHEMBL4774579

[c]1ccc(NCCc2ccccc2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ACHE P22303 3/20 0.43
RPS27 P42677 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
APP P05067 2/20 0.42
EGFR P00533 1/20 0.42
MAPK1 P28482 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
RCE1 Q9Y256 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769908 0.85 SMN1; SMN2 (0.43) HTTSMN1; SMN2
SCHEMBL4775118 0.83 L3MBTL1 (0.47) L3MBTL1KDM4ERAB9A
SCHEMBL988776 0.83 FABP1 (0.58) L3MBTL1LMNAMAPK1KDM4EMEN1
SCHEMBL4775077 0.80 CHRM2 (0.55) HTTSMN1; SMN2RAB9ATAAR1
SCHEMBL4776298 0.80 CYP1A2 (0.69) LMNAAPPALDH1A1MAPTRAB9A
SCHEMBL4777990 0.75 CHEK1 (0.37) EGFRKDM4ESMN1; SMN2CDK8
SCHEMBL29594283 0.75 CYP1A2 (0.68) HTR7L3MBTL1ACHEKDM4EMEN1
SCHEMBL182723 0.75 KDM4E (0.42) LMNAEGFRMAPK1KDM4EMEN1
SCHEMBL991740 0.75 HCAR3 (0.44) L3MBTL1LMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL15904158 0.75 CYP1A2 (0.68) HTR7L3MBTL1ACHEKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A HTR7 314/4885L3MBTL1 4590/4885ACHE 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.